Docetaxel News and Research

RSS

Docetaxel is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of breast and non-small cell lung cancer (NSCLC). It is also approved to be used with other drugs to treat squamous cell carcinoma of the head and neck (SCCHN) and certain types of gastric and prostate cancer.

Docetaxel is a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree Taxus baccata. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent.

Genentech submits sBLAs to the FDA for Avastin

Genentech, Inc., a wholly-owned member of the Roche Group, today announced that the company submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer (first-line treatment). One sBLA is based on the Phase III study AVADO that investigated Avastin in combination with docetaxel chemotherapy.

17 Nov 2009

Capecitabine in chemotherapy regimen reduces early breast cancer recurrence

An analysis conducted by the Finnish Breast Cancer Group and published in The Lancet Oncology shows women at intermediate to high-risk of early breast cancer recurrence who received capecitabine as part of their chemotherapy regimen had a 34% reduction in the risk of the disease returning or death, compared with those taking the chemotherapy combination regimen without capecitabine.

11 Nov 2009

Combination therapy before prostate removal may prevent recurrence of cancer

Researchers in the Oregon Health & Science University Knight Cancer Institute and the Portland Veterans Affairs Medical Center have found a combination of radiation therapy and chemotherapy given before prostate removal is safe and may have the potential to reduce cancer recurrence and improve patient survival.

4 Nov 2009

NeoPharma submits a Phase II protocol to the FDA for its liposome entrapped docetaxel study

NeoPharm, Inc. today announced that it has submitted a Phase II protocol to the FDA for the study of liposome entrapped docetaxel (LE-DT), a novel, proprietary liposomal delivery system of docetaxel, the active ingredient of Taxotere®, for locally advanced or metastatic pancreatic cancer patients.

27 Oct 2009

Astellas enters into agreement with Medivation to develop MDV3100

Astellas Pharma Inc. ("Astellas") and Medivation, Inc. announced today that they have entered into a global agreement to develop and commercialize MDV3100, Medivation's investigational drug for the treatment of prostate cancer.

27 Oct 2009

Peregrine Pharmaceuticals reports positive results from Phase II trial of bavituximab

Peregrine Pharmaceuticals, Inc. today reported positive results from its Phase II trial evaluating bavituximab in combination with docetaxel in patients with advanced breast cancer.

22 Oct 2009

Phyton Biotech purchases NPI’s assets

Phyton Biotech, LLC (Phyton), an affiliate of Phyton, Inc., today announced that it has purchased the assets of Natural Pharmaceuticals, Inc. (NPI), a leading manufacturer of oncology drug active pharmaceutical ingredients (API’s).

13 Oct 2009

OncoGenex' OGX-011 receives additional FDA Fast Track Designation for treating metastatic prostate cancer

OncoGenex Pharmaceuticals, Inc. announced today that OGX-011, also known as custirsen sodium, received an additional Fast Track Designation from the U.S. Food & Drug Administration (FDA) for progressive metastatic prostate cancer in combination with first-line docetaxel treatment.

6 Oct 2009

Medivation commences patient treatment in clinical trial of MDV3100 in advanced prostate cancer

Medivation, Inc. (Nasdaq: MDVN) today announced treatment of the first patient in a Phase 3 clinical trial of the investigational drug MDV3100 in advanced prostate cancer. Known as AFFIRM, the trial will evaluate the novel androgen receptor antagonist MDV3100 in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy.

24 Sep 2009

Sanofi-aventis and Regeneron Pharmaceuticals discontinue Phase 3 trial of aflibercept

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. today announced the discontinuation of the Phase 3 trial that evaluated aflibercept (VEGF Trap) plus gemcitabine versus placebo plus gemcitabine for the first-line treatment of metastatic pancreatic cancer (VANILLA), based on the recommendations by an Independent Data Monitoring Committee (IDMC).

14 Sep 2009

FDA approves Supplemental New Drug Application for DOXIL

Centocor Ortho Biotech Products, L.P. today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its Supplemental New Drug Application (sNDA) for DOXIL (doxorubicin HCI liposome injection) in combination with docetaxel for the treatment of women with locally advanced and metastatic breast cancer.

10 Sep 2009

Patient enrollment completed in Phase II clinical trial of bavituximab

Peregrine Pharmaceuticals, Inc. today reported completion of patient enrollment in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in advanced breast cancer patients.

9 Sep 2009

Researchers reveal that genes contributing to drug resistance in NSCLC disease could be predicted

The genes that may contribute to drug resistance in non-small cell lung cancer (NSCLC) can be predicted. Researchers writing in the open access journal BMC Cancer found good correlation between genes believed to be involved in drug sensitivity and resistance and actual in vitro chemosensitivity.

26 Aug 2009

Genentech announces Phase III study results for Avastin (bevacizumab) in combination with chemo in HER2-negative breast cancer

Genentech, Inc. today announced that a Phase III study (RIBBON 2) of Avastin (bevacizumab) in combination with chemotherapy increased the time women with metastatic HER2-negative breast cancer whose initial chemotherapy had stopped working lived without the disease worsening (progression-free survival or PFS), compared to chemotherapy alone.

18 Aug 2009

ADVENTRX Pharmaceuticals announces closing of financing

ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that it has completed the previously announced sale of shares of its 5% Series C convertible preferred stock pursuant to a registered direct offering to a single institutional investor, representing gross proceeds of approximately $0.9 million.

10 Aug 2009

Array Biopharma reports Q4 and full year 2009 financials

Array reported revenue of $5.5 million for the fourth quarter of fiscal 2009, compared to revenue of $6.1 million for the same period in fiscal 2008. Array invested $21.3 million in proprietary research and development for the quarter to advance its seven wholly-owned drugs in clinical development and select discovery programs.

10 Aug 2009

Gene that stops or suppress cancer plays a role in cancer stem cells

A gene well known to stop or suppress cancer plays a role in cancer stem cells, according to a new study from the University of Michigan Comprehensive Cancer Center. The researchers found that several pathways linked to the gene, called PTEN, also affected the growth of breast cancer stem cells.

1 Jun 2009

Vandetanib shows clinical benefit when combined with docetaxel for lung cancer

When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas M. D. Anderson Cancer Center.

1 Jun 2009

Study shows that induction chemotherapy prior to chemoradiotherapy significantly increases time-to-treatment failure in comparison to standard chemoradiotherapy alone

The Spanish Head and Neck Cancer Cooperative Group (TTCC) announced today that Induction Chemotherapy (IC) delivered prior to standard ChemoRadiotherapy (CRT), a treatment paradigm defined as sequential therapy, compared to upfront CRT alone, significantly prolonged Time-to-Treatment Failure (TTF) for patients with unresectable Locally Advanced Head and Neck Cancer (LAHNC).

1 Jun 2009

Iressa (gefinitib) chemotherapy combination proves safe for head and neck cancer patients

Patients undergoing treatment for advanced head and neck cancers may respond well to the addition of gefinitib to chemotherapy, according to a study sponsored by the Eastern Cooperative Oncology Group and chaired by Ethan Argiris, M.D., associate professor of medicine, University of Pittsburgh School of Medicine, and co-leader of the Head and Neck Cancer Program of the University of Pittsburgh Cancer Institute (UPCI).

31 May 2009

Docetaxel News and Research

Further Reading

Genentech submits sBLAs to the FDA for Avastin

Capecitabine in chemotherapy regimen reduces early breast cancer recurrence

Combination therapy before prostate removal may prevent recurrence of cancer

NeoPharma submits a Phase II protocol to the FDA for its liposome entrapped docetaxel study

Astellas enters into agreement with Medivation to develop MDV3100

Peregrine Pharmaceuticals reports positive results from Phase II trial of bavituximab

Phyton Biotech purchases NPI’s assets

OncoGenex' OGX-011 receives additional FDA Fast Track Designation for treating metastatic prostate cancer

Medivation commences patient treatment in clinical trial of MDV3100 in advanced prostate cancer

Sanofi-aventis and Regeneron Pharmaceuticals discontinue Phase 3 trial of aflibercept

FDA approves Supplemental New Drug Application for DOXIL

Patient enrollment completed in Phase II clinical trial of bavituximab

Researchers reveal that genes contributing to drug resistance in NSCLC disease could be predicted

Genentech announces Phase III study results for Avastin (bevacizumab) in combination with chemo in HER2-negative breast cancer

ADVENTRX Pharmaceuticals announces closing of financing

Array Biopharma reports Q4 and full year 2009 financials

Gene that stops or suppress cancer plays a role in cancer stem cells

Vandetanib shows clinical benefit when combined with docetaxel for lung cancer

Study shows that induction chemotherapy prior to chemoradiotherapy significantly increases time-to-treatment failure in comparison to standard chemoradiotherapy alone

Iressa (gefinitib) chemotherapy combination proves safe for head and neck cancer patients

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News